By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panel is divided on P&G's $3.8B acquisition of Thorne, with concerns about the high price, execution risks, and limited capex for Thorne's DTC infrastructure, but also seeing potential in Thorne's premium wellness products and practitioner relationships.
Risk: Limited capex for Thorne's DTC infrastructure and potential margin squeeze
Opportunity: Premiumizing P&G’s existing health portfolio using Thorne’s clinical data
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Procter & Gamble (NYSE:PG) is buying its way into wellness. On August 4, L Catterton announced it had signed a definitive agreement to sell Thorne, a science-backed health and wellness brand, to Procter & Gamble for $3.8 billion in cash. The deal lands a day after an August 3 analysis flagged a fiscal 2027 earnings guide that came in below expectations, weighed down by roughly $1 billion in new cost headwinds. Investors now have two stories to weigh at once: fresh expansion and a tougher near-term cost picture.
The Thorne acquisition gives Procter & Gamble entry into a category built on clinical credibility rather than shelf space. Thorne has spent 40 years building relationships with healthcare practitioners, and L Catterton's announcement noted the company developed a proprietary AI wellness advisor to help consumers navigate its supplement lineup, a tool practitioners can point their patients to directly.
The transaction is expected to close in the fourth quarter of 2026, an all-cash deal with no debt or equity swapped into the mix. Procter & Gamble isn't skimping on shareholders while it shops, either. The company returned $10.2 billion in dividends and $5.0 billion in share repurchases during fiscal 2026, and it plans roughly the same combination, about $10 billion in dividends and $5 billion in buybacks, for fiscal 2027. There's a case buried inside the company's own guidance, too. Strip out the roughly $1 billion in commodity, energy, and transportation costs management expects to absorb next year, and core EPS would be growing at about 10% instead of the 0% to 3% baked into the outlook.
The numbers behind the fiscal 2027 outlook explain the caution. Management guided core EPS to $6.89 to $7.11, implying growth of just 0% to 3%, and pointed to roughly $1 billion in after-tax commodity, energy, and transportation costs as the main culprit. Add higher net interest expense, lower non-operating income, and unfavorable currency, and the total drag reaches $0.56 per share, wiping out about 8 percentage points of core earnings growth before the year even starts.
The trend already shows up in recent results. In the fiscal fourth quarter, net sales rose 2% year-over-year to $21.2 billion while organic sales were flat, and core EPS fell 3% to $1.43. For the full fiscal year, net sales grew 3% to $87.0 billion, but organic sales rose only 1%, and every bit of that growth came from higher prices rather than more units sold. Volume and mix didn't move. Shares trade near $144, about 5% above their 52-week low of $137.62, or roughly 21 times fiscal 2026 core earnings of $6.89. That's not an expensive multiple, but it isn't cheap for a business guiding to low-single-digit growth.
Four leading AI models discuss this article
"Underlying 10% core growth is masked by transitory $1B cost headwinds, but sustained negative volume trends and a delayed close keep valuation from being compelling."
P&G's $3.8B all-cash Thorne acquisition (closing Q4 2026) is a smart, high-quality entry into practitioner-trusted supplements and AI-driven personalization, a category growing far faster than core consumer staples. The fiscal 2027 EPS guide of 0-3% looks ugly because it bakes in a full $1B after-tax cost hit plus $0.56/share in other drags, but stripping those out reveals ~10% underlying growth. At 21x fiscal 2026 EPS the stock is not demanding; returning $15B in dividends and buybacks again in FY27 shows capital discipline. The real risk is whether volume/mix can finally inflect once pricing fatigue eases.
The deal closes two years from now while investors must endure another year of flat-to-low-single-digit EPS growth and continued negative volume trends; $3.8B spent on a niche brand may prove too small to move the needle on an $87B revenue base if macro cost pressures persist or Thorne integration disappoints.
"P&G is overpaying for wellness to distract from the fundamental failure of its core business to generate organic volume growth."
P&G is attempting a classic 'quality pivot' to mask stagnant organic volume. While the Thorne acquisition adds a premium, high-margin wellness vertical that justifies a higher multiple, the $3.8B price tag is steep for a company struggling to move units. The core issue isn't just the $1B in commodity headwinds; it’s the reliance on price hikes to drive revenue, which has reached a ceiling. At 21x forward earnings, investors are paying for growth that isn't showing up in volume. Unless Thorne’s AI-driven practitioner model can scale rapidly into mass retail, this deal looks like a defensive maneuver to buy growth rather than a catalyst for organic expansion.
If Thorne’s clinical credibility allows P&G to capture the GLP-1 weight-loss supplement market, the $3.8B valuation could look like a bargain compared to the long-term recurring revenue of a health-focused consumer base.
"PG is overpaying for category expansion while its core business shows zero volume growth and trading at a multiple that offers no margin of safety if Thorne integration disappoints or cost pressures persist longer than expected."
PG is paying 1.9x sales for Thorne—a 40-year-old brand with practitioner relationships and an AI advisor tool—while guiding to 0-3% core EPS growth. Strip the $1B commodity/energy headwind and you get ~10% underlying growth, which is respectable. The real tension: PG is returning $15B to shareholders while absorbing $3.8B in M&A, yet organic sales grew just 1% last year with zero volume growth. The Thorne bet assumes PG can cross-sell wellness into its 2B+ consumer touchpoints, but that requires execution in an unfamiliar category. At 21x forward earnings on low-single-digit guidance, the stock prices in neither the cost headwinds nor meaningful upside from Thorne.
If commodity costs normalize faster than expected in 2027 and Thorne's practitioner network actually drives meaningful DTC velocity, PG could surprise to 8-10% EPS growth by 2028, justifying today's multiple. The article frames guidance as weak, but it's conservative relative to what stripping out transitory costs suggests.
"Durable, cross-channel top-line growth from Thorne is the only plausible path to justify a $3.8B cash bet, given near-term headwinds and a rich multiple."
Procter & Gamble signals a strategic shift into credibility-based wellness by buying Thorne for $3.8B in cash, aiming to monetize practitioner channels and an AI wellness advisor. The upside would come from higher-margin, premium wellness products and leverage of PG’s distribution; if the synergy hits, core EPS could grow from a stronger wellness portfolio even with existing headwinds. But near-term risks are meaningful: about $1B of cost headwinds are baked into fiscal 2027 guidance, and the cash deal limits liquidity and optionality. Thorne’s growth depends on driving real volume, regulatory stability, and successful cross-selling—areas with execution risk in a competitive, price-sensitive space. The result may be a wait-and-see for 2026-27.
The premium paid could prove unjustified if Thorne fails to convert practitioner relationships into durable, high-volume sales, and the cash outlay constrains PG’s balance sheet and buyback potential when headwinds persist.
"Thorne's premium valuation assumes flawless mass-channel scaling that history shows rarely succeeds without destroying the practitioner pricing power."
Claude's 1.9x sales multiple for Thorne ignores that the $3.8B is paid in 2026 dollars after two more years of likely negative volumes and persistent pricing fatigue. The $15B shareholder return commitment actually tightens the balance sheet for integration capex. Nobody has flagged that practitioner DTC brands have historically failed to scale into mass channels without heavy promotion, eroding the very premium margins cited.
"Thorne’s value lies in clinical data and brand defensibility, not mass-market scale."
Grok, you're right about the mass-market friction, but everyone is ignoring the regulatory moat. Thorne’s 'practitioner-trusted' status isn't just marketing; it’s a barrier to entry that shields it from the private-label commoditization currently crushing P&G’s core brands. Gemini, if P&G tries to force Thorne into mass retail, they’ll destroy the brand equity. The real value isn't scaling Thorne to mass; it's using Thorne’s clinical data to premiumize P&G’s existing, stagnant health portfolio. The M&A is a defensive R&D play.
"Thorne's moat is narrower than claimed, and P&G's capital allocation constraints may starve the brand of the investment needed to defend practitioner relationships."
Gemini's regulatory moat argument is overstated. Thorne's 'practitioner-trusted' positioning is defensible but not a durable moat—competitors like Orthomolecular, Designs for Health, and even Amazon's private label are gaining practitioner share. The real risk: P&G's $15B shareholder return commitment leaves minimal capex for Thorne's DTC infrastructure. If Thorne needs $200-300M annually to defend its channel, that's a margin squeeze nobody quantified.
"Thorne's moat isn't durable; success depends on rapid, costly cross-sell adoption and capex, not solely the credibility of practitioner channels or a high-price tag."
Gemini argued a regulatory moat could justify the price. I’d push back: moat durability is unproven; even with practitioner trust, scaling cross-sell into mass channels requires heavy data/integration spend and regulatory/compliance costs that aren’t captured in the 0-3% guide. And the $15B share repurchase limits optionality—if Thorne revenue overshoots, capital returns could suffer. Bottom line: the deal hinges on real, fast-scale adoption, not just credibility.
The panel is divided on P&G's $3.8B acquisition of Thorne, with concerns about the high price, execution risks, and limited capex for Thorne's DTC infrastructure, but also seeing potential in Thorne's premium wellness products and practitioner relationships.
Premiumizing P&G’s existing health portfolio using Thorne’s clinical data
Limited capex for Thorne's DTC infrastructure and potential margin squeeze